Agreement - February 10, 2021
Medivir licenses preclinical program to Ubiquigent
Ubiquigent has entered into a license agreement with Medivir for Medivir’s preclinical USP7 research program. Under the terms of the agreement, Medivir has granted Ubiquigent an exclusive worldwide license to develop and commercialize the program including all associated compounds across any therapeutic indication(s) in return for agreed revenue share upon successful development or commercialization by […]
COVID-19 - August 17, 2020
Medivir and SciLifeLab collaborate on potential SARS CoV-2 inhibitors
Medivir has entered a research collaboration with the Drug Discovery and Development Platform (DDD) at SciLifeLab on potential inhibitors of SARS CoV-2. Through the collaboration, DDD will get access to Medivir’s protease-targeted compound library, states the company in its press release. Data will be released on-line The aim of the collaboration is to find potential […]
Clinical Trials - March 2, 2020
Medivir presents positive data
Medivir has presented new data from the completed phase Ia study with MIV-818. The primary objective of the phase Ia study was to evaluate safety and tolerability of MIV-818 in liver cancer patients. A total of nine patients with advanced disease were included: six patients with metastatic liver cancer, two with hepatocellular carcinoma and one […]
Clinical Trials - January 22, 2020
Medivir phase II study published in Annals of Internal Medicine
Medivir has announced that the phase II study of MIV-711 in patients with osteoarthritis has been published in the journal Annals of Internal Medicine. The title of the article is “Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis”, author; P.G Conaghan et al. In the same issue there is an editorial by J.N […]
Pharma Award - December 10, 2019
Medivir wins the International Diamond Prize for Excellence in Quality
Medivir has announced that the company has been awarded the International Diamond Prize for Excellence in Quality 2019. The Prize, run by the European Society for Quality Research (ESQR), recognizes the companies, public administrations and organizations, with superior development efforts and overall excellence, which are most committed to economic progress, both for themselves and their […]
In a new job - May 3, 2019
Medivir appoints new CFO
The company has announces the appointment of Magnus Christensen as new CFO of Medivir effective as of 12 August 2019. Christensen will also join the company’s management team. In his role, he will be responsible for Investor Relations as well as leading the day-to-day operations within the areas of finance, IT, HR and premises. Magnus […]
